Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

28.6%

2 terminated/withdrawn out of 7 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Phase 1
6(85.7%)
Phase 3
1(14.3%)
7Total
Phase 1(6)
Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT06375044Phase 1Recruiting

Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma

Role: collaborator

NCT06331559Phase 1Terminated

Study of SIM0501 Alone and in Combination in Patients With Advanced Solid Tumors

Role: collaborator

NCT06792552Phase 1Recruiting

A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors

Role: collaborator

NCT04908787Phase 3Completed

A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer

Role: collaborator

NCT06186414Phase 1Recruiting

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC

Role: collaborator

NCT06686745Phase 1Recruiting

Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors

Role: collaborator

NCT05781360Phase 1Terminated

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors

Role: collaborator

All 7 trials loaded